OSI/Roche warn of GI, skin and eye problems with Tarceva
This article was originally published in Scrip
Executive Summary
OSI Pharmaceuticals/Roche (formerly Genentech) are warning doctors about the risk of gastrointestinal perforations, serious skin reactions and ocular disorders with the EGFR-targeted oncologic Tarceva (erlotinib).